Evidence map›Paper›PMID 36346670›Full record

ArticleJCI insight2022

NKG2D receptor activation drives primary graft dysfunction severity and poor lung transplantation outcomes.

Daniel R Calabrese, Tasha Tsao, Mélia Magnen, Colin Valet, Ying Gao, Beñat Mallavia, Jennifer J Tian, Emily A Aminian, Kristin M Wang, Avishai Shemesh and 21 more

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in JCI insight, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Lung allograft dysbiosis associates with immune response and primary graft dysfunction.The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2025
    Article
  7. Article
  8. Article
  9. CD94The European respiratory journal · 2024
    Article
  10. Article
  11. Macrophage and CD8 T cell discordance are associated with acute lung allograft dysfunction progression.The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2024
    Article
  12. Natural Killer Cell Ligands: Another Source of Heterogeneity in Acute Lung Injury Pathophysiology?American journal of respiratory and critical care medicine · 2024
    Article
  13. American journal of respiratory and critical care medicine · 2024
    Observational
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors at 3 institutions in 1 country.

Daniel R CalabreseDepartment of Medicine, San Francisco Veterans Affairs Medical Center, San Francisco, California, USA.
Tasha TsaoDepartment of Medicine, UCSF, San Francisco, California, USA.
Mélia MagnenDepartment of Medicine, UCSF, San Francisco, California, USA.
Colin ValetDepartment of Medicine, UCSF, San Francisco, California, USA.
Ying GaoDepartment of Medicine, UCSF, San Francisco, California, USA.
Beñat MallaviaDepartment of Medicine, UCSF, San Francisco, California, USA.
Jennifer J TianDepartment of Medicine, UCSF, San Francisco, California, USA.
Emily A AminianDepartment of Medicine, UCSF, San Francisco, California, USA.
Kristin M WangDepartment of Medicine, UCSF, San Francisco, California, USA.
Avishai ShemeshDepartment of Medicine, UCSF, San Francisco, California, USA.
Elman B PunzalanDepartment of Medicine, UCLA, Los Angeles, California, USA.
Aartik SarmaDepartment of Medicine, UCSF, San Francisco, California, USA.
Carolyn S CalfeeDepartment of Medicine, UCSF, San Francisco, California, USA.
Stephanie A ChristensonDepartment of Medicine, UCSF, San Francisco, California, USA.
Charles R LangelierDepartment of Medicine, UCSF, San Francisco, California, USA.
Steven R HaysDepartment of Medicine, UCSF, San Francisco, California, USA.
Jeffrey A GoldenDepartment of Medicine, UCSF, San Francisco, California, USA.
Lorriana E LeardDepartment of Medicine, UCSF, San Francisco, California, USA.
Mary Ellen KleinhenzDepartment of Medicine, UCSF, San Francisco, California, USA.
Nicholas A KolaitisDepartment of Medicine, UCSF, San Francisco, California, USA.
Rupal ShahDepartment of Medicine, UCSF, San Francisco, California, USA.
Aida VenadoDepartment of Medicine, UCSF, San Francisco, California, USA.
Lewis L LanierParker Institute for Cancer Immunotherapy, San Francisco, California, USA.
John R GreenlandDepartment of Medicine, San Francisco Veterans Affairs Medical Center, San Francisco, California, USA.
David M SayahDepartment of Medicine, UCLA, Los Angeles, California, USA.
Abbas ArdehaliDepartment of Medicine, UCLA, Los Angeles, California, USA.
Jasleen KukrejaDepartment of Surgery, UCSF, San Francisco, California, USA.
S Samuel WeigtDepartment of Medicine, UCLA, Los Angeles, California, USA.
John A BelperioDepartment of Medicine, UCLA, Los Angeles, California, USA.
Jonathan P SingerDepartment of Medicine, UCSF, San Francisco, California, USA.
Mark R LooneyDepartment of Medicine, UCSF, San Francisco, California, USA.
University of California, San Francisco · USSan Francisco VA Medical Center · USParker Institute for Cancer Immunotherapy · US

Funding

Immunobiology of the normal and injured lungR35HL161241 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MARK ROBERTS LOONEY · 2022 to 2026
$4.2M
Airway epithelial cell and lymphocyte interactions in chronic lung allograft dysfunction pathogenesisR01HL161048 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JOHN GREENLAND, TEREZA MARTINU · 2022 to 2026
$3.3M
Innate Immune Mechanisms of Primary Graft Dysfunction after Lung TransplantationR01HL130324 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LOONEY, MARK ROBERTS · 2016 to 2019
$2.2M
Natural killer cells in pulmonary ischemia-reperfusion injuryIK2BX005301 · VA · VETERANS AFFAIRS MED CTR SAN FRANCISCO · PI Daniel Calabrese · 2021 to 2026
–
BLRD VA IK2 BX005301CSRD VA I01 CX002011NHLBI NIH HHS R01 HL130324NHLBI NIH HHS R01 HL161048NHLBI NIH HHS R35 HL161241
6 · The paper itself

Abstract

Clinical outcomes after lung transplantation, a life-saving therapy for patients with end-stage lung diseases, are limited by primary graft dysfunction (PGD). PGD is an early form of acute lung injury with no specific pharmacologic therapies. Here, we present a large multicenter study of plasma and bronchoalveolar lavage (BAL) samples collected on the first posttransplant day, a critical time for investigations of immune pathways related to PGD. We demonstrated that ligands for NKG2D receptors were increased in the BAL from participants who developed severe PGD and were associated with increased time to extubation, prolonged intensive care unit length of stay, and poor peak lung function. Neutrophil extracellular traps (NETs) were increased in PGD and correlated with BAL TNF-α and IFN-γ cytokines. Mechanistically, we found that airway epithelial cell NKG2D ligands were increased following hypoxic challenge. NK cell killing of hypoxic airway epithelial cells was abrogated with NKG2D receptor blockade, and TNF-α and IFN-γ provoked neutrophils to release NETs in culture. These data support an aberrant NK cell/neutrophil axis in human PGD pathogenesis. Early measurement of stress ligands and blockade of the NKG2D receptor hold promise for risk stratification and management of PGD.

Indexed as

Lung TransplantationPrimary Graft DysfunctionHumansLungNK Cell Lectin-Like Receptor Subfamily KTumor Necrosis Factor-alphaNK Cell Lectin-Like Receptor Subfamily KTumor Necrosis Factor-alphaImmunologyNeutrophilsNK cellsOrgan transplantationPulmonology

Identifiers

PMID36346670
PMCPMC9869973
OpenAlexW4308523670

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.